Prenetics

Prenetics is a NASDAQ-listed genomics-driven health sciences company, specializing in prevention, early detection, and treatment of diseases. Its prevention arm, CircleDNA, leverages next-generation sequencing for comprehensive DNA testing. In collaboration with renowned scientist Prof. Dennis Lo, Prenetics also focuses on multi-cancer early detection technologies through its $200 million venture, Insighta. Additionally, its treatment unit, ACT Genomics, is the first Asia-based company to achieve FDA clearance for genomic profiling of solid tumors, emphasizing its global impact on health and commitment to enhancing life through science.